US EditionIndia to tackle global obesity with cheap fat-loss jabs
India's generic semaglutide launch may reduce treatment costs to $60 monthly, expanding access amid rising obesity and projected $500 million sales by 2030, experts say.
- India's patent expiry on March 20 has opened immediate launch options as a key semaglutide patent expired, prompting 'Day 1' launches by Zydus Lifesciences.
- Rising obesity and fast sales growth have driven market pressure, with government data showing 24 percent of women and 23 percent of men overweight or obese in last year, and India's domestic market sales reaching $214 million by 2026.
- Industry filings show at least four major Indian firms are readying generics, with Pharmarack's Sheetal Sapale saying, 'What we understand is, there will be more than 50 brands that will be launched in the market and there are more than 40 players who will be launching these drugs'.
- Clinicians say lower prices could sharply expand patient access as Dr Swati Pradhan expects clinic caseloads to rise from 70–80 to 200 with generics cutting costs from 20,000 rupees monthly.
- Pending patent expiries through the end of 2026 broaden global generic opportunities, with 10 countries representing 48 percent of the global obesity burden and India supplying over half of Africa's generics.
32 Articles
32 Articles
Malay Mail
AlKhaleej TodayIndia set to roll out cheap weight-loss jabs as demand rises amid obesity surge
MUMBAI, March 20 — A deluge of weight-loss drugs is set to transform the global fight against obesity as India prepares to unleash low-cost generic versions of injections like Ozempic after a key patent expired today.The move will dramatically widen access to treatments that have long been considered a luxury, especially in middle-income countries, where soaring demand has collided with steep prices.At clinics across Mumbai, doctors say they are…
The peptide, which has proven highly effective for type 2 diabetes and obesity, will be priced lower than the patented version. Regeneración, 19 […] The entry India will release Ozempic for generic use at affordable prices was first published on RegeneraciónMX.
Coverage Details
Bias Distribution
- 58% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
